Chonluten — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Chonluten

Also known as: Chonluten tripeptide, Khavinson Peptide (bronchial)

Ultrashort signaling peptide (tripeptide); Khavinson Peptide

Research chemicalLast updated: October 19, 2026Based on 3 peer-reviewed studiesPreclinical data only — no human trials

What it is

Chonluten is a short peptide studied in Russian research for lung protection and immune modulation, particularly in the context of aging and respiratory inflammation. Evidence is limited to cell culture and early animal studies. No FDA-approved use; limited independent research outside of the original research group.

The scientific side

Chonluten is a tripeptide originally isolated from bronchial epithelial cells and characterized as organ-specific. In vitro studies show it modulates inflammatory and proliferative processes: it increases tyrosine phosphorylation of mitogen-activated cytoplasmic kinases, inhibits TNF production in LPS-stimulated monocytes (linked to a documented mechanism of TNF tolerance), suppresses pro-inflammatory IL-6 cytokine expression in terminally differentiated macrophages, and reduces monocyte adhesion to LPS-activated endothelial cells. As an ultrashort peptide (2–7 amino acid residues), it is proposed to act as a signaling molecule regulating gene expression and protein synthesis, and may be transported into cells via POT (PEPT1, PEPT2, PHT1, PHT2) and/or LAT family transporters, a mechanism thought to underlie tissue specificity and geroprotective action.

Class: Ultrashort signaling peptide (tripeptide); Khavinson Peptide

Administration & storage

Administration
In vitro incubation (cell culture medium) (PMID: 35408963)
Storage
No storage conditions for Chonluten are described in the reviewed abstracts.
Cautions
No human pharmacokinetic or safety data for Chonluten are reported in the reviewed abstracts — clinical safety profile is unknown.,All efficacy data derive from in vitro cell culture studies; translation to human use has not been established in the reviewed literature.,The reviewed literature does not address formulation purity, sterility standards, or acceptable excipients for any route of administration.,Sterile technique is universally required for any injectable preparation; failure to maintain sterility poses infection risk regardless of the compound used.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification

WADA

Not stated in reviewed literature — requires manual verification

Health Canada

Not stated in reviewed literature — requires manual verification